| Members |
targetComponentId |
| Horseradish - dietary |
Horseradish (substance) |
| Hospital physicist |
Medical physicist |
| Hospital physicist |
Medical physicist |
| Hot comb alopecia |
Central centrifugal cicatricial alopecia (disorder) |
| Hot environment |
Hot environment |
| Hottentot |
Khoikhoi |
| Hottentot language |
Khoisan language |
| House dust allergy vaccine |
House dust allergy vaccine (product) |
| House mite allergy vaccine |
House mite allergy vaccine (product) |
| Human adenovirus 40 antigen |
Antigen of Human mastadenovirus F (substance) |
| Human adenovirus 41 antigen |
Antigen of Human mastadenovirus F (substance) |
| Human alpha1 proteinase inhibitor 1000mg powder for injection solution vial |
Human alpha1 proteinase inhibitor 1 g powder for solution for injection vial |
| Human alpha1 proteinase inhibitor 500mg injection solution vial + diluent |
Human alpha1 proteinase inhibitor 500 mg powder for solution for injection vial |
| Human alpha1 proteinase inhibitor 500mg powder for conventional release solution for injection vial |
Human alpha1 proteinase inhibitor 500 mg powder for solution for injection vial |
| Human chorionic gonadotropin 10,000iu powder and solvent for injection solution vial |
Product containing precisely human chorionic gonadotropin 10000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human coronavirus HK1 |
Human coronavirus HKU1 |
| Human epidermal growth factor 2 expressing colon and/or rectum malignant neoplasm |
Malignant neoplasm of colorectum expressing human epidermal growth factor 2 |
| Human herpesvirus 1 group virus |
Simplexvirus |
| Human herpesvirus 3 group virus |
Genus Varicellovirus (organism) |
| Human immunodeficiency virus |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus (HIV) infection category B1 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category A1 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B1 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category C1 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus World Health Organization class I |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 1 |
| Human immunodeficiency virus World Health Organization class II |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 2 |
| Human immunodeficiency virus World Health Organization class III |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 3 (finding) |
| Human immunodeficiency virus World Health Organization class IV (acquired immunodeficiency syndrome) |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 4 (finding) |
| Human immunodeficiency virus World Health Organization class finding |
World Health Organization human immunodeficiency virus infection clinical stage (finding) |
| Human immunodeficiency virus seropositivity |
Human immunodeficiency virus detected (finding) |
| Human immunodeficiency virus type 2 |
Human immunodeficiency virus type 2 |
| Human immunodeficiency virus type I |
Human immunodeficiency virus type I |
| Human immunodeficiency virus, type II glycoprotein 53 antibody |
Human immunodeficiency virus 2 protein 53 antibody (substance) |
| Human immunodeficiency virus-associated periodontitis |
Periodontitis exacerbated by human immunodeficiency virus infection (disorder) |
| Human immunoglobulin IgG 200mg/mL solution for injection |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 10% injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 10g injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 10g powder for injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 16% injection solution vial |
Product containing precisely human immunoglobulin G 160 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Human immunoglobulin g 2.5g powder for injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 20g injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human immunoglobulin g 5g powder for injection solution vial |
Product containing only human immunoglobulin G (medicinal product) |
| Human insulin 1mg unit dose blister dry powder for inhalation |
Human insulin-containing product |
| Human insulin 3mg unit dose blister dry powder for inhalation |
Human insulin-containing product |
| Human interferon gamma-1b 200 micrograms/mL injection solution 0.5mL vial |
Interferon gamma-1b 200 microgram/mL solution for injection |
| Human interferon gamma-1b adverse reaction |
Adverse reaction to interferon gamma-1b |
| Human leukocyte antigen A 3101 present |
Human leukocyte antigen A*31:01 detected (finding) |
| Human leukocyte antigen B 1502 present |
HLA-B*15:02 detected |
| Human leukocyte antigen B 5701 present |
HLA-B*57:01 detected |
| Human leukocyte antigen absent |
HLA antigen |
| Human menopausal gonadotrophins 150iu injection |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 150iu injection |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 150units(FSH) injection (pdr for recon)+solvent |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 75iu injection |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human menopausal gonadotrophins 75iu injection |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human menopausal gonadotrophins 75units(FSH) powder and solvent for injection solution vial |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human normal immunoglobulin 10g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 10g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 10g infusion solution vial |
Product containing precisely human immunoglobulin G 10 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 12g infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 16% injection solution vial |
Product containing precisely human immunoglobulin G 160 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 1g infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g infusion solution vial |
Product containing precisely human immunoglobulin G 2.5 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 250mg injection solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 3g infusion solution vial |
Product containing precisely human immunoglobulin G 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 500mg i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 500mg i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 500mg infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g infusion solution vial |
Product containing precisely human immunoglobulin G 5 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 6g conventional release solution for injection vial |
Human immunoglobulin G 6 G powder for solution for injection vial |
| Human normal immunoglobulin 6g infusion solution vial |
Human immunoglobulin G 6 G powder for solution for injection vial |
| Human normal immunoglobulin 750mg injection solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human papilloma virus type 9 vaccine |
Vaccine product containing only Human papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 antigens (medicinal product) |
| Human papillomavirus group |
Human papillomavirus |
| Human papillomavirus test declined |
Screening for Human papillomavirus declined (situation) |
| Human protein C 1000iu injection (pdr for recon)+solvent |
Product containing precisely human protein C 1000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 1000iu injection powder for reconstitution+solvent |
Product containing precisely human protein C 1000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 500iu injection (pdr for recon)+solvent |
Product containing precisely human protein C 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 500iu injection powder for reconstitution+solvent |
Product containing precisely human protein C 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein-induced anaphylaxis |
Anaphylaxis |
| Human recombinant choriogonadotropin alfa 250micrograms injection powder for reconstitution + solvent |
Choriogonadotropin alfa only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 1 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 10 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 2 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 5 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human vaccination |
Active immunization |
| Human vaccinia immune globulin 50mg/mL injection solution 50mL vial |
Vaccinia human immune globulin 50 mg/mL solution for injection |
| Humid environment |
Humid environment (finding) |
| Humulin insulin adverse reaction |
Adverse reaction caused by human insulin (disorder) |
| Husband of subject |
Husband |
| Hyaline membrane disease |
Respiratory distress syndrome in the newborn |
| Hyaluronidase 1500unt/10mL injection |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hyaluronidase 150unt/mL injection solution 10mL vial |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hyaluronidase 150unt/mL injection solution 1mL vial |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hydatidiform mole, no International Classification of Diseases for Oncology subtype |
Hydatidiform mole, benign (morphologic abnormality) |
| Hydralazine hydrochloride 20mg injection powder vial |
Hydralazine hydrochloride 20 mg powder for solution for injection vial |
| Hydrazide antituberculosis agent |
Antituberculosis agent |
FHIR